Sun Pharma, India’s largest drugmaker, is looking at acquisitions to boost its specialty pipeline and strengthen emerging markets business. “Our focus on M&A will be on augmenting the pipeline for specialty and further strengthening our footprint in emerging markets,” said CS Muralidharan, chief financial officer of Sun Pharma.
